116 Retinal Disorders - Milton Keynes Formulary

• Home
• Chapters
  • 1. Gastro-Intestinal System
  • 2. Cardiovascular system
  • 3. Respiratory System
  • 4. Nervous System
  • 5. Infections
  • 6. Endocrine System
  • 7. Obstetrics, Gynaecology and Urinary-tract Disorders
  • 8. Immune System and Malignant Disease
  • 9. Nutrition and Blood
  • 10. Musculoskeletal and Joint Diseases
  • 11. Eye
  • 12. Ear, Nose and Oropharynx
  • 13. Skin
  • 14. Immunological Products and Vaccines
  • 15. Anaesthesia
  • 16 Wound Management
  • 17. Miscellaneous Preparations
• Drugs
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z
• MK Prescribing Advisory Group (MKPAG)
  • Application Forms
  • MKPAG Ratified Minutes
  • MKPAG Meeting Dates
  • Terms of Reference (ToR)
  • M&TC Minutes
• NICE Adherence Checklist
• GP Prescribing Group
  • Terms of reference
  • Minutes
  • Archived Minutes
• Shared Care Guidelines
• Local & National General Prescribing Information
  • 1. Financial and clinical responsibility for prescribing non-formulary drugs
  • 2. Repeat Prescribing Code of Practice
  • 3. When not to prescribe generically
  • 4. MK CCG Commissioning Policies
  • 5. Borderline Substances (ACBS)
  • 6. Selective List Scheme (SLS)
  • 7. Overseas visitors
  • 8. Travelling abroad
  • 9. Liquid Specials
  • 10. SPS Drug Monitoring Document Oct 2017
  • 11. Medication Information in Practices-November 2017
  • 12. Drugs That Prolong QT Interval
  • 13 Consultation Letter to Schools Nurseries-June 2017
  • 14 Letter to parents re changes in prescribing
  • 15. Self-Care Medicine List
• Biosimilar Position Statement
• Unlicensed Medicines
• Copyright Notice
• Patient Information Leaflets (New)
• About the Formulary Local Decisions
  • About the Joint Formulary
  • Format of the Formulary and Traffic Light Classification
• Newsletters
• Useful Links
• Contact Us

11.6 Retinal Disorders

Traffic light status (TLS) explained:

• Green: Routine prescribing within licensed indication
• Amber 1: specialist recommendation followed by GP initiation and continuation
• Amber 2: specialist or GP initiation in line with local guideline after 1st line failure followed by GP continuation
• Amber 3: specialist initiation and stabilisation followed by GP continuation
• Amber SCG: specialist initiation and stabilisation followed by GP continuation in line with an agreed shared care guideline
• Red: Hospital or specialist prescribing only
• Double Red: These medicines have been evaluated and rejected by MKPAG and are NOT approved for use within MK. They are not recommended for use because of lack of clinical effectiveness, cost effectiveness or safety.

11.6.1 Macular Degeneration

Aflibercept

• Eylea^® Solution for intravitreal injection, 40mg per 1mL vials

Notes:

• Use as per NICE TA486: Aflibercept for treating choroidal neovascularisation (November 2017)

• Use as per NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (September 2016)

• Use as per NICE TA346: Aflibercept for treating diabetic macular oedema (July 2015)

• Use as per NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion(February 2014)

• Use as per NICE TA294: Aflibercept solution for injection for treating wet age‑related macular degeneration (July 2013)

Ranibizumab

• Lucentis^® 10mg/mL solution for injection in pre-filled syringe

Notes:

• Use as per NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (May 2012)

• Use as per NICE TA274:Ranibizumab for treating diabetic macular oedema(February 2013)

• Use as per NICE TA283: Macular oedema (retinal vein occlusion) - ranibizumab (May 2013)

• Use as per NICE TA298: Choroidal neovascularisation (pathological myopia) - ranibizumab (November 2013)

Verteporfin

• Injection powder for reconstitution 15mg vial

Notes:

• Use as per NICE TA68: Photodynamic therapy for wet age-related macular degeneration (Sept 2003)

.

11.6.2 Macular oedema

Fluocinolone acetonide

• Iluvien^® Intravitreal implant containing fluocinolone acetonide 190 micrograms in a disposable applicator

Notes:

• Use as per NICE TA301: Diabetic macular oedema - fluocinolone acetonide intravitreal implant (rapid review of TA271) (November 2013)

11.6.4 Vitreomacular traction

Ocriplasmin (Amber 2)

• Injection 125mcg  

Notes:

• Use as per NICE TA297: Ocriplasmin for treating vitreomacular traction (Oct 2013)

Traffic light status (TLS) explained:

• Green: Routine prescribing within licensed indication
• Amber 1: specialist recommendation followed by GP initiation and continuation
• Amber 2: specialist or GP initiation in line with local guideline after 1st line failure followed by GP continuation
• Amber 3: specialist initiation and stabilisation followed by GP continuation
• Amber SCG: specialist initiation and stabilisation followed by GP continuation in line with an agreed shared care guideline
• Red: Hospital or specialist prescribing only
• Double Red: These medicines have been evaluated and rejected by MKPAG and are NOT approved for use within MK. They are not recommended for use because of lack of clinical effectiveness, cost effectiveness or safety.

Return to Chapter: 11. Eye

Last updated by: Sheila Wood on 13-02-2019 13:57